Phase 2 Triple Negative Breast Cancer trials recruiting now

All Triple Negative Breast Cancer trials, every phase

Other phases for Triple Negative Breast Cancer

Phase 2 Triple Negative Breast Cancer trials

• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
  NCT06492005 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
  NCT05902988 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
  NCT04501523 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
  NCT06471205 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
  NCT07768436 · Phase: Phase 2 · Ages: 70 Years and older · Sex: All (male and female) · 7 locations
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
  NCT04683679 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 7 locations
• A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
  NCT06926920 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study of Tetrathiomolybdate (TM) Plus Capecitabine
  NCT06134375 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 3 locations
• A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
  NCT04481763 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
  NCT06682793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
  NCT07115043 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
  NCT07281976 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
  NCT06224673 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
  NCT04437160 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
  NCT05192798 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Female · 1 location
• Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
  NCT05296564 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
  NCT04434040 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
  NCT06690840 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer
  NCT07108309 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: Female · 47 locations
• CTS2190 Phase I /II Clinical Study in Patients
  NCT06224387 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer
  NCT06367088 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer
  NCT05475678 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
  NCT07510802 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
  NCT07401537 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
  NCT07340541 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• FUSCC Refractory TNBC Platform Study (FUTURE2.0)
  NCT05749588 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
  NCT04677816 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
  NCT06358573 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
  NCT06954480 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
  NCT03808337 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• JS207 Combination Therapy in Triple-negative Breast Cancer
  NCT07045311 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 22 locations
• MicroRNA Profiles in Triple Negative Breast Cancer
  NCT04771871 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations
• Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
  NCT05329532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer
  NCT04159142 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
  NCT04138719 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
  NCT06845319 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
  NCT06225284 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
  NCT06353997 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
  NCT07283692 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
  NCT05485766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
  NCT06318897 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
  NCT06245889 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• PRE-ISPY Phase I/II Oncology Platform Program
  NCT05868226 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
  NCT07739485 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
  NCT05491083 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 99 Years · Sex: All (male and female) · 1 location
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
  NCT06078384 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 44 locations
• Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
  NCT06631092 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
  NCT04787042 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
  NCT06460298 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Reverse Triple Negative Immune Resistant Breast Cancer
  NCT05076682 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
• Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
  NCT04468061 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Sacituzumab Govitecan In TNBC
  NCT04230109 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
  NCT06238921 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
  NCT04768426 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
  NCT04947189 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
  NCT05447702 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Study of Screening Brain MRIs in Stage IV Breast Cancer
  NCT05115474 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations
• The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer
  NCT05550415 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
  NCT06538896 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
  NCT05846789 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
  NCT06291064 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 4 locations
• Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
  NCT07064018 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Triple Negative Breast Cancer and Celecoxib. Pilot Study
  NCT07104266 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.